nach oben

Erschienen in:

13.03.2018 | Hepatobiliary-Pancreas

Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study

verfasst von: Zhenwei Peng, Mengchao Wei, Shuling Chen, Manxia Lin, Chunlin Jiang, Jie Mei, Bin Li, Yu Wang, Jiaping Li, Xiaoyan Xie, Ming Kuang

Erschienen in: European Radiology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To compare retrospectively the efficacy of transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) (TACE-RFA) with that of repeat hepatectomy in the treatment of initial recurrent hepatocellular carcinoma (HCC) after hepatectomy by propensity score matching (PSM).

Methods

From September 2006 to June 2015, 186 patients who underwent TACE-RFA (n=107) or repeat hepatectomy (n=79) for recurrent HCC ≤ 5.0 cm were included. The overall survival (OS) and disease-free survival (DFS) were compared. PSM was used to correct potential confounding factors between these two groups.

Results

1-, 3-, and 5-year OS rates after TACE-RFA and repeat hepatectomy were 84.6%, 66.9%, 49.1%, and 84.8%, 60.2%, 51.9%, respectively (p=.871). The corresponding DFS rates were 58.2%, 35.2%, 29.6% and 64.8%, 41.6%, 38.3% (p=.258). TACE-RFA has lower major complication rates (p=.009) and shorter hospital stay (p<.001). After PSM, 1-, 3-, 5- year OS rates after TACE-RFA (n=51) and repeat hepatectomy (n=51) were 84.3%, 60.4%, 46.4% and 84.3%, 64.5%, 49.8% (p=.951), the corresponding DFS rates were 54.9%, 35.0%, 30.6% and 58.7%, 35.8%, and 33.6% (p=.733). AFP and micro-vessel invasion of initial tumour were significant prognostic factors for OS and DFS, respectively.

Conclusions

TACE-RFA provides comparable OS and DFS to repeat hepatectomy, fewer major complications and shorter hospital stay.

Key Points

• TACE-RFA achieved similar OS and DFS with repeat hepatectomy for recurrent HCC

• Major complication rate was lower in the TACE-RFA group

• The hospital stay was shorter in the TACE-RFA group

• AFP was a predictor for OS, MVI was a predictor for DFS

• The treatment strategies were not significant prognostic factor for OS or DFS

Nur mit Berechtigung zugänglich

Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917CrossRefPubMed

Itamoto T, Nakahara H, Amano H et al (2007) Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 141:589–597CrossRefPubMed

Camma C, Di Marco V, Orlando A et al (2005) Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 42:535–540CrossRefPubMed

Poon RT, Fan ST, Tsang FH, Wong J (2002) Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 235:466–486CrossRefPubMedPubMedCentral

Song KD, Lim HK, Rhim H et al (2015) Repeated Hepatic Resection versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Hepatic Resection: A Propensity Score Matching Study. Radiology 275:599–608CrossRefPubMed

Tateishi R, Shiina S, Teratani T et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103:1201–1209CrossRefPubMed

Peng ZW, Zhang YJ, Chen MS et al (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432CrossRefPubMed

Kim JH, Won HJ, Shin YM et al (2011) Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 18:1624–1629CrossRefPubMed

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116:5452–5460CrossRefPubMed

10.

Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700CrossRefPubMed

11.

Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252:905–913CrossRefPubMed

12.

Kagawa T, Koizumi J, Kojima S et al (2010) Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 116:3638–3644CrossRefPubMed

13.

Yamakado K, Nakatsuka A, Takaki H et al (2008) Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 247:260–266CrossRefPubMed

14.

D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281CrossRefPubMed

15.

Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRefPubMed

16.

Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J (2015) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One 10:e0119312CrossRefPubMedPubMedCentral

17.

Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351–355CrossRefPubMed

18.

Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumour ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology 273:241–260CrossRefPubMedPubMedCentral

19.

Sobin LHWC (2002) TNM Classification of Malignant Tumours. John Wiley, Hoboken, NJ

20.

Cancer NIO (2010) Common Terminology Criteria for Adverse Events ( CTCAE ).

21.

Omary RA, Bettmann MA, Cardella JF et al (2003) Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. J Vasc Interv Radiol 14:S293–S295CrossRefPubMed

22.

Kang TW, Kim JM, Rhim H et al (2015) Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes. Radiology 275:908–919CrossRefPubMed

23.

Kang TW, Lim HK, Lee MW et al (2016) Long-term Therapeutic Outcomes of Radiofrequency Ablation for Subcapsular versus Nonsubcapsular Hepatocellular Carcinoma: A Propensity Score Matched Study. Radiology 280:300–312CrossRefPubMed

24.

Takuma Y, Takabatake H, Morimoto Y et al (2013) Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology 269:927–937CrossRefPubMed

25.

Chang WT, Kao WY, Chau GY et al (2012) Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery 152:809–820CrossRefPubMed

26.

Park YN (2011) Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 135:704–715CrossRefPubMed

27.

Goldberg SN, Hahn PF, Tanabe KK et al (1998) Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 9:101–111CrossRefPubMed

28.

Higuchi T, Kikuchi M, Okazaki M (1994) Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer 73:2259–2267CrossRefPubMed

29.

Yamashiki N, Yoshida H, Tateishi R et al (2007) Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J Gastroenterol Hepatol 22:2155–2160CrossRefPubMed

30.

Huang ZY, Liang BY, Xiong M et al (2012) Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-centre experience in China. Ann Surg Oncol 19:2515–2525CrossRefPubMed

31.

Lim KC, Chow PK, Allen JC et al (2011) Microvascular invasion is a better predictor of tumour recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 254:108–113CrossRefPubMed

Titel: Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study
verfasst von: Zhenwei Peng
Mengchao Wei
Shuling Chen
Manxia Lin
Chunlin Jiang
Jie Mei
Bin Li
Yu Wang
Jiaping Li
Xiaoyan Xie
Ming Kuang
Publikationsdatum: 13.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 8/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-017-5166-4

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study